Laboratory Medical Billing Reference: CPT Codes and Coverage Rules

Laboratory medical billing encompasses a distinct and technically demanding segment of the healthcare revenue cycle, governed by specific CPT code ranges, payer coverage policies, and federal regulations that differ substantially from evaluation and management or surgical billing. This reference covers the principal CPT code categories used for laboratory services, the coverage determination frameworks applied by Medicare and commercial payers, common claim scenarios that generate denials, and the decision boundaries that separate billable from non-billable laboratory work. Accurate laboratory billing is consequential: the Department of Health and Human Services Office of Inspector General (OIG) has consistently identified clinical laboratory billing as a high-risk area in its annual Work Plan.

Definition and scope

Laboratory billing refers to the process of coding, submitting, and collecting payment for diagnostic tests performed on specimens — blood, urine, tissue, and other biological materials — using the procedural coding structure maintained by the American Medical Association (AMA). The AMA CPT code set designates the 80000–89999 series as Pathology and Laboratory codes. This range is further subdivided into panels, chemistry tests, hematology, immunology, microbiology, surgical pathology, and molecular diagnostics.

Laboratory services are billed under two primary claim form contexts depending on provider type. Independent and reference laboratories — those not hospital-affiliated — typically bill on the CMS-1500 form, while hospital outpatient laboratories bill on the UB-04 under inpatient or outpatient billing rules. This structural distinction directly affects which fee schedules apply and how the claim is adjudicated.

The Centers for Medicare & Medicaid Services (CMS) administers the Clinical Laboratory Fee Schedule (CLFS), which sets payment rates for over 1,000 laboratory test codes under Medicare Part B. The Protecting Access to Medicare Act of 2014 (PAMA) (Public Law 113-93) restructured CLFS rate-setting to tie payment amounts to weighted median private payer rates reported by applicable laboratories.

How it works

Laboratory billing follows a discrete sequence of steps, each with compliance checkpoints enforced by payer policy and federal statute.

  1. Test order and medical necessity documentation — A licensed ordering provider generates a test requisition. CMS requires that a written or electronic order exist prior to billing and that the test be medically necessary as defined by Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) issued by CMS (coverage database).
  2. Specimen collection and CPT code assignment — The performing laboratory assigns CPT codes to each test performed. A venipuncture (CPT 36415) may be separately billable in addition to the test code, subject to payer rules. Automated chemistry panels use defined panel codes (e.g., CPT 80053 for Comprehensive Metabolic Panel) rather than individual component codes, to comply with bundling and unbundling rules.
  3. Diagnosis linkage via ICD-10-CM — Each CPT code must be linked to a supporting ICD-10 diagnosis code that establishes medical necessity for that specific test. Mismatched diagnosis-to-test pairings are a primary trigger for LCD-based denials.
  4. ABN issuance when applicable — If a test may not meet Medicare coverage criteria, the laboratory must issue an Advance Beneficiary Notice of Noncoverage (ABN) (CMS ABN instructions, Form CMS-R-131) before the test is performed. Absent a valid ABN, the laboratory cannot bill the beneficiary if Medicare denies the claim.
  5. Claim submission — Claims are submitted electronically via a clearinghouse using the 837P transaction format (HIPAA compliance standards) or on paper using CMS-1500, with Box 21 containing diagnosis codes and Box 24D containing procedure codes.
  6. Remittance review and denial response — The payer returns a remittance advice (ERA) with payment or denial reason codes. Denial management follows structured appeal pathways governed by payer contracts and, for Medicare, the multi-level appeals process codified at 42 C.F.R. Part 405, Subpart I.

Common scenarios

Reflex and add-on testing: When an initial test result triggers a follow-up test without a new physician order, this is termed reflex testing. CMS requires that the original order explicitly authorize reflexing, or a new order must be obtained. Billing reflex tests without documented authorization is a documented compliance vulnerability cited in OIG advisory opinions.

Molecular diagnostics and genomic testing: CPT codes 81161–81408 cover molecular pathology procedures ranging from single gene analysis to multigene panels. These codes carry specific coverage conditions under Medicare, and many require prior authorization under commercial plans. Genomic Sequence Analysis Panels (CPT 81432–81479) are subject to individual LCD review in each Medicare Administrative Contractor (MAC) jurisdiction.

Specimen referral to reference laboratories: When a laboratory collects a specimen but sends it to a reference lab for analysis, the collecting laboratory may bill only for collection; the reference laboratory bills for the technical and professional components of the test. Passing through reference lab charges at a marked-up rate is prohibited under the Medicare reassignment rules at 42 C.F.R. §424.80.

Payer-specific coverage restrictions: Commercial payers may apply coverage policies that differ from Medicare LCDs. Understanding these distinctions is part of effective commercial insurance billing. For Medicare Advantage plans, Medicare Advantage billing policies may layer plan-specific rules on top of the CLFS.

Decision boundaries

The central distinction in laboratory billing is between covered and non-covered services, which is not inherent to the test itself but is determined by the combination of the ordering diagnosis, the payer's LCD or NCD, and the patient's benefit plan.

A secondary distinction separates professional component from technical component billing. Surgical pathology (CPT 88300–88309) and cytopathology codes carry a professional component (modifier -26) billed by the pathologist and a technical component (modifier -TC) billed by the facility. In a global billing context, neither modifier is appended. This mirrors the component structure used in radiology billing.

A third boundary exists between screening and diagnostic tests. Routine screening laboratory tests (e.g., a lipid panel ordered as part of preventive care) may fall under Medicare Part B preventive benefit codes rather than the CLFS, changing both the applicable fee schedule and the patient cost-sharing obligation. Screening tests billed with a diagnostic ICD-10 code, or diagnostic tests billed as preventive, constitute a fraud and abuse risk under the False Claims Act (31 U.S.C. §§ 3729–3733).

Laboratories operating under the Clinical Laboratory Improvement Amendments (CLIA) (42 C.F.R. Part 493) must hold a valid CLIA certificate corresponding to the complexity of tests performed. Medicare and Medicaid will not reimburse laboratory services from a laboratory operating without an appropriate CLIA certificate — making CLIA status a non-negotiable billing prerequisite, not merely a clinical one. The provider credentialing and enrollment process includes CLIA certificate verification for laboratory providers.

References

📜 7 regulatory citations referenced  ·  🔍 Monitored by ANA Regulatory Watch  ·  View update log

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator